Market Research Report
Tigecycline Market: by Application (Skin & Soft Tissue Infections, Complicated Intra-abdominal Infections, and Community-acquired Bacterial Infection); Target Bacteria Type (Gram Positive and Gram Negative) and Geography - Forecast 2019-2024
|Published by||IndustryARC||Product code||410606|
Delivery time: 2-3 business days
|Tigecycline Market: by Application (Skin & Soft Tissue Infections, Complicated Intra-abdominal Infections, and Community-acquired Bacterial Infection); Target Bacteria Type (Gram Positive and Gram Negative) and Geography - Forecast 2019-2024|
|Published: December 5, 2018||Content info:||
Tigecycline is a broad spectrum glycylcycline type acting as a protein synthesis inhibitor. Tigecycline blocks the interaction of aminoacyl-tRNA with the A site of the ribosome by binding to the 30S ribosomal subunit of bacteria and thus exhibits bacteriostatic activity. Additionally, Tigecycline is shown to exhibit bactericidal activity against isolates of L. pneumophila and S. pneumoniae.
Tigecycline is used to treat a variety of bacterial infections and thus acts as an antibiotic. Tigecycline is a first glycylcycline type that is administered intravenously. The main reason for the discovery of Tigecycline is the rising rate of antibiotic resistance in a number of bacteria such as Acinetobacter baumannii, Staphylococcus aureus, and E. coli. Tigecycline is a tetracycline derivative antibiotic and thus its structural modifications have extended its theraoeutic activity to include Gram-negative and Gram-positive bacteria, comprising those of multi-drug resistance. The increasing demand for Tigecycline as an antibiotic is expected to fuel the market growth over the forecast period.
Tigecycline is recommended by the European Society of Clinical Microbiology and Infection as a potential salvage therapy for complicated and severe refractory Clostridium difficile infection. Tigecycline also finds application in treatment of immune-compromised patients or patients having cancer. Even more, tigecycline have potential for use in acute myeloid leukemia. Tigecycline is prescribed at every 12 hours with slow intravenous infusion. Patients suffering with impaired liver function needs to be prescribed a lower dose of tigecycline. No adjustments are needed for patients suffering with impaired kidney function.
The global Tigecycline market is classified into applications as Skin & Soft-tissue Infections, Complicated Intra-abdominal Infections and Community-acquired Bacterial Pneumonia. In addition, the global Tigecycline market is further bifurcated on the basis of target bacteria type into Gram Positive Bacteria and Gram Negative Bacteria.
Lastly, the global tigecycline market is bifurcated by regions as North America, Asia Pacific (APAC), Europe and Rest of the World (RoW). Presently, the global tigecycline market is dominated by Asia-Pacific region primarily due to a significant adoption of tigecycline as an antibiotic in pharmaceuticals industry. The APC region is also expected to continue its dominance in the market during the forecast period. The European and North American regions are also analyzed to witness a healthy growth rate in the global tigecycline market during the forecast period.
Pfizer Inc. (U.S.)
Hisun Pharma (U.S.)
Hansoh Pharma (China)
Jiagsu Aosaikang Pharmaceutical Co. Ltd. (China)
Abbott Laboratories (U.S.) among others.
More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"